BridgeMD
New treatment option for Juvenile Idiopathic Arthritis
Official title A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
ClinicalTrials.gov ID: NCT03773965
What this study is testing
What is Baricitinib?
Baricitinib is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for juvenile idiopathic arthritis.
Also referred to as LY3009104.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 1 to 18
You may be able to join if
- Participants must have completed a previous study of baricitinib for the treatment of JIA.
You likely can't join if
- Participants must not have had a permanent discontinuation of baricitinib in the prior study.
- Participants must have not developed an allergy to baricitinib.
The study team makes the final eligibility decision.
Where it's taking place
- Rosario, Argentina
- SAN M. de Tucuman, Argentina
- Melbourne, Australia
- Perth, Australia
- Westmead, Australia
- Bregenz, Austria
- Brussels, Belgium
- Ghent, Belgium
- Leuven, Belgium
- Botucatu, Brazil
- São Paulo, Brazil
- Beijing, China
- Chongqing, China
- Nanjing, China
- Suzhou, China
- Brno, Czechia
- Prague, Czechia
- Aarhus, Denmark
- Bron, France
- Le Kremlin-Bicêtre, France
+ 52 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 1 year to 18 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rosario, Argentina; SAN M. de Tucuman, Argentina; Melbourne, Australia; Perth, Australia; Westmead, Australia; Bregenz, Austria and 66 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.